BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - BridgeBio Pharma reported preliminary unaudited Q4 and Full Year 2025 net product revenue of $146.0 million and $362.4 million, respectively, indicating strong commercial performance for its product Attruby (acoramidis) [1] - Attruby is becoming the preferred therapy for newly diagnosed ATTR-CM patients, with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, driven by its differentiated clinical data [1] - The company announced a new TTR amyloid depleter antibody program aimed at exploring the potential for ATTR-CM disease reversal, with clinical advancement expected between 2027 and 2028 [1] - The interim analysis from the FORTIFY Phase 3 study of BBP-418 in LGMD2I/R9 showed a statistically significant 2.6 point benefit on NSAD relative to placebo at 12 months, leading the FDA to recommend a traditional full approval pathway [1] - A rapid increase in the diagnosis of ADH1 has been observed, with over 1,700 unique patients identified since October 2023, prompting the company to plan an NDA submission based on CALIBRATE trial results in the first half of 2026 [1] - The initiation of the RECLAIM-HP Phase 3 trial of encaleret in chronic hypoparathyroidism is scheduled for summer 2026 following a completed End of Phase 2 interaction with the FDA [1] - The company achieved LPLV for PROPEL 3, with topline results expected by the end of Q1 2026, and LPI for the Phase 2 portion of ACCEL 2/3 [1] - As of December 31, 2025, the company had approximately $587.5 million in cash, cash equivalents, and marketable securities, positioning it well to support the acceleration of Attruby and potentially launch three additional medicines globally [1] Company Overview - BridgeBio Pharma is a biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines for genetic diseases, founded in 2015 [6] - The company emphasizes a decentralized model to drive impact across various communities, aiming to double the number of patients served by the end of 2026 [2]